Observational Study on Lutetium (177Lu) Vipivotide Tetraxetan to Treat Metastatic Castration Resistant Prostate Cancer
Recruiting · NCT07093801 · Observational (researchers observe without assigning treatment) · Lead sponsor: Novartis Pharmaceuticals
View the official record on ClinicalTrials.gov →What this trial is about
This is a local prospective, multicenter, long-term, non-interventional study using primary data collection to describe the routine clinical practice of patients with mCRPC treated with lutetium (177Lu) vipivotide tetraxetan. The observation period will be from date of start of treatment up to a maximum of 18 months after end of treatment.
Who can take part
Age range
18 Years to 99 Years
Sex
Male
Healthy volunteers
No - a diagnosis or condition is required
Phase
Not specified
Study type
Observational (researchers observe without assigning treatment)
Eligibility criteria (as published)
1. Adult patients diagnosed with mCRPC eligible for and prescribed with lutetium (177Lu) vipivotide tetraxetan by the treating physician (Multidisciplinary Team).
2. ≥ 18 years old at the time of enrollment.
3. Written informed consent must be obtained to participate to this study
In addition to the above-listed criteria, no other inclusion/exclusion criteria exist other than the requirements stated in the local Summary of Product Characteristics (SmPC) and in the "Scheda di Monitoraggio AIFA", e.g., contraindications.
Where it is running
34 locations listed.
- Novartis Investigative Site - Milan, Italy
- Novartis Investigative Site - Naples, Italy
- Novartis Investigative Site - Alessandria, AL, Italy
- Novartis Investigative Site - Asti, AT, Italy
- Novartis Investigative Site - Bergamo, BG, Italy
- Novartis Investigative Site - Brescia, BS, Italy
- Novartis Investigative Site - Catania, CT, Italy
- Novartis Investigative Site - Meldola, FC, Italy
- Novartis Investigative Site - Cona, FE, Italy
- Novartis Investigative Site - Foggia, FG, Italy
- Novartis Investigative Site - Florence, FI, Italy
- Novartis Investigative Site - Genova, GE, Italy
- Novartis Investigative Site - Genova, GE, Italy
- Novartis Investigative Site - Latina, LT, Italy
- Novartis Investigative Site - Province of Macerata, MC, Italy
- Novartis Investigative Site - Milan, MI, Italy
- Novartis Investigative Site - Milan, MI, Italy
- Novartis Investigative Site - Rozzano, MI, Italy
- Novartis Investigative Site - Palermo, PA, Italy
- Novartis Investigative Site - Padova, PD, Italy
- Novartis Investigative Site - Perugia, PG, Italy
- Novartis Investigative Site - Pisa, PI, Italy
- Novartis Investigative Site - Aviano, PN, Italy
- Novartis Investigative Site - Rionero in Vulture, PZ, Italy
- Novartis Investigative Site - Reggio Emilia, RE, Italy
- Novartis Investigative Site - Roma, RM, Italy
- Novartis Investigative Site - Roma, RM, Italy
- Novartis Investigative Site - Roma, RM, Italy
- Novartis Investigative Site - Roma, RM, Italy
- Novartis Investigative Site - La Spezia, SP, Italy
- Novartis Investigative Site - Taranto, TA, Italy
- Novartis Investigative Site - Torino, TO, Italy
- Novartis Investigative Site - Mestre, VE, Italy
- Novartis Investigative Site - Negrar, VR, Italy